Neuronal markers in the cerebrospinal fluid suggest the degree of white-matter damage correlates with time needed for recovery, and that repetitive brain injury spurs amyloid deposition.
With a laser focus on biomarkers and disease mechanisms, researchers at the 10th ICFTD meeting prepared the ground for therapeutic studies.
Researchers report that tau accumulation in the cortex associates with cognitive impairment in people with ongoing synucleinopathy. Aβ is not necessary for this type of tauopathy.
P25 overexpression in APP transgenic mice is one of perhaps many artifacts of APP overexpression, APP, researchers charge. Do APP/PS1 transgenic mouse phenotypes need re-evaluation?
Newly ensconced at the National Institute on Aging’s Division of Neuroscience, Masliah urges researchers to participate “at all levels” in the community-driven process to implement the national plan. His lure? Finally, more money.
Researchers explain why the protease cuts at every third amino acid, shedding light on how some familial APP mutations are pathogenic.
New evidence suggests that Aβ trimers cause tau to misfold, then together, the soluble miscreants gum up axonal transport.
Parabiosis passes its first test in mouse models of Alzheimer’s, normalizing gene expression and improving memory—though with no reduction in amyloid plaques.
As research on frontotemporal dementia gathers steam, the international conference hosted its largest gathering ever last month in Munich. More than 750 researchers shared their latest data on basic science, genetics, and clinical outcome measures. Biomarkers dominated the meeting, as the field prepares for therapy trials by seeking better ways to track pathology in living people. The few trials that have been done thus far, without specific biomarkers, have largely been a bust. Read Madolyn Rogers’ coverage.
Since replacing Neil Buckholtz and, more recently, Tony Phelps at the National Institute on Aging in Bethesda, Maryland, this summer, Eliezer Masliah has familiarized himself with the agency’s myriad programs and funding mechanisms. His is arguably a good problem to have: How best to ramp up as new money finally rolls in to a long-starved research field? What are Masliah’s priorities, and how can dementia researchers best interact with him? Read our Q&A.
The ideal participants in a secondary prevention trial still have their wits about them, but are highly likely to develop Alzheimer’s symptoms in the next few years. How do you tell a person that? While searching for thousands of such people to fill their studies, trial leaders are also studying procedures for disclosing to would-be participants the results of their personal AD biomarker tests. At AAIC, researchers shared emerging evidence about the ethical, psychological, and social impact of disclosing risk conferred either by amyloid status or ApoE genotype. Beyond trials, ethical disclosure procedures will be crucial if a disease-modifying therapy is approved—at that point, scores of patients, maybe millions around the globe, will want to know their status.
- Michael Sasner on Do APP Knock-ins Call Overexpression Models of AD into Question?
- Takaomi Saido on Do APP Knock-ins Call Overexpression Models of AD into Question?
- Johannes Attems on Tau Deepens Cognitive Trouble in Lewy Body Diseases
- Keith Vossel on Singling Out Aβ Assemblies: Focus on Trimers
- Kejal Kantarci on Tau Deepens Cognitive Trouble in Lewy Body Diseases
- Tanis Ferman on Tau Deepens Cognitive Trouble in Lewy Body Diseases
- Karen Hsiao Ashe on Do APP Knock-ins Call Overexpression Models of AD into Question?
- Li-Huei Tsai on Do APP Knock-ins Call Overexpression Models of AD into Question?
- Jianxing Song on Helical Tail Holds Sway Over TDP-43 Packaging
- Takaomi Saido on Paper Alert: Aducanumab Phase 1b Study Published
- Jacek Kuznicki on Mutant Presenilin Skews Calcium Homeostasis by Chomping on ER Sensor
- Ilya Bezprozvanny on Mutant Presenilin Skews Calcium Homeostasis by Chomping on ER Sensor
- Takaomi Saido on Aggregation-Prone Gene Expression Signature Mapped in Brain
- Bruno Pietro Imbimbo on Paper Alert: Aducanumab Phase 1b Study Published
- Michael Parker on Paper Alert: Aducanumab Phase 1b Study Published
- Lon S. Schneider on Paper Alert: Aducanumab Phase 1b Study Published
- Philip Landfield on Epigenetic Tracer Uncovers Patterns of Healthy Gene Regulation
- Einar Sigurdsson, Erin Congdon, Ayodeji Asuni and Dov Shamir on Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.
- Marco Cecchi on Staging of Alzheimer’s, the Second: Neurodegeneration Does Not Equal Tauopathy
- Takaomi Saido on New Ways to Target Aβ and BACE Show Promising Phase 1 Data
- Mark Jenkinson on Software Flaw Casts Doubt on Past Task fMRI Studies